182 related articles for article (PubMed ID: 17448875)
1. Characterizing the tumor response to treatment with combretastatin A4 phosphate.
Salmon BA; Siemann DW
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):211-7. PubMed ID: 17448875
[TBL] [Abstract][Full Text] [Related]
2. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.
Salmon HW; Siemann DW
Clin Cancer Res; 2006 Jul; 12(13):4090-4. PubMed ID: 16818709
[TBL] [Abstract][Full Text] [Related]
3. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model.
Malcontenti-Wilson C; Muralidharan V; Skinner S; Christophi C; Sherris D; O'Brien PE
Clin Cancer Res; 2001 Apr; 7(4):1052-60. PubMed ID: 11309357
[TBL] [Abstract][Full Text] [Related]
4. Combretastatin A4 phosphate: a novel vascular disrupting agent.
Nagaiah G; Remick SC
Future Oncol; 2010 Aug; 6(8):1219-28. PubMed ID: 20799867
[TBL] [Abstract][Full Text] [Related]
5. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
[TBL] [Abstract][Full Text] [Related]
6. The development of combretastatin A4 phosphate as a vascular targeting agent.
Chaplin DJ; Hill SA
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1491-6. PubMed ID: 12459376
[TBL] [Abstract][Full Text] [Related]
7. A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers.
Abma E; De Spiegelaere W; Vanderperren K; Stock E; Van Brantegem L; Cornelis I; Daminet S; Ni Y; Vynck M; Verstraete G; Smets P; de Rooster H
Vet Comp Oncol; 2018 Dec; 16(4):467-477. PubMed ID: 29797763
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
[TBL] [Abstract][Full Text] [Related]
9. Quantitative Evaluation of Combretastatin A4 Phosphate Early Efficacy in a Tumor Model with Dynamic Contrast-Enhanced Ultrasound.
Zhang P; Chen Y; Liu J; Yang Y; Lv Q; Wang J; Zhang L; Xie M
Ultrasound Med Biol; 2018 Apr; 44(4):840-852. PubMed ID: 29395676
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of vascular targeting by inhibitors of nitric oxide synthase.
Davis PD; Tozer GM; Naylor MA; Thomson P; Lewis G; Hill SA
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1532-6. PubMed ID: 12459382
[TBL] [Abstract][Full Text] [Related]
11. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
McPhail LD; Griffiths JR; Robinson SP
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1238-45. PubMed ID: 17967313
[TBL] [Abstract][Full Text] [Related]
12. Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model.
Jockovich ME; Bajenaru ML; Piña Y; Suarez F; Feuer W; Fini ME; Murray TG
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2476-82. PubMed ID: 17525173
[TBL] [Abstract][Full Text] [Related]
13. Monitoring the treatment efficacy of the vascular disrupting agent CA4P.
Salmon BA; Salmon HW; Siemann DW
Eur J Cancer; 2007 Jul; 43(10):1622-9. PubMed ID: 17451938
[TBL] [Abstract][Full Text] [Related]
14. Combretastatin A4 phosphate.
West CM; Price P
Anticancer Drugs; 2004 Mar; 15(3):179-87. PubMed ID: 15014350
[TBL] [Abstract][Full Text] [Related]
15. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.
Vincent L; Kermani P; Young LM; Cheng J; Zhang F; Shido K; Lam G; Bompais-Vincent H; Zhu Z; Hicklin DJ; Bohlen P; Chaplin DJ; May C; Rafii S
J Clin Invest; 2005 Nov; 115(11):2992-3006. PubMed ID: 16224539
[TBL] [Abstract][Full Text] [Related]
16. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
Siemann DW; Chaplin DJ; Walicke PA
Expert Opin Investig Drugs; 2009 Feb; 18(2):189-97. PubMed ID: 19236265
[TBL] [Abstract][Full Text] [Related]
17. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors.
Murata R; Siemann DW; Overgaard J; Horsman MR
Radiother Oncol; 2001 Aug; 60(2):155-61. PubMed ID: 11439210
[TBL] [Abstract][Full Text] [Related]
18. Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging.
Nielsen T; Bentzen L; Pedersen M; Tramm T; Rijken PF; Bussink J; Horsman MR; Østergaard L
Clin Cancer Res; 2012 Dec; 18(23):6469-77. PubMed ID: 23071260
[TBL] [Abstract][Full Text] [Related]
19. Dynamic bioluminescence and fluorescence imaging of the effects of the antivascular agent Combretastatin-A4P (CA4P) on brain tumor xenografts.
Liu L; Mason RP; Gimi B
Cancer Lett; 2015 Jan; 356(2 Pt B):462-9. PubMed ID: 25305449
[TBL] [Abstract][Full Text] [Related]
20. Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo.
Yao N; Ren K; Jiang C; Gao M; Huang D; Lu X; Lou B; Peng F; Yang A; Wang X; Ni Y; Zhang J
Tumour Biol; 2015 Nov; 36(11):8499-510. PubMed ID: 26026583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
